End-of-day quote
Other stock markets
|
||
- USD | - |
|
05-21 | Lineage Cell Therapeutics, Inc. Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium | CI |
05-09 | Transcript : Lineage Cell Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Sales 2024 * | 12.22M 967M | Sales 2025 * | 5.87M 464M | Capitalization | 188M 14.89B |
---|---|---|---|---|---|
Net income 2024 * | -29M -2.29B | Net income 2025 * | -32M -2.53B | EV / Sales 2024 * | 15.4 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 32.1 x |
P/E ratio 2024 * |
-7.67
x | P/E ratio 2025 * |
-5.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.56% |
Latest transcript on BioTime, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Brian Culley
CEO | Chief Executive Officer | 53 | 16/09/18 |
Jill Howe
DFI | Director of Finance/CFO | 48 | 13/11/22 |
Chief Operating Officer | - | 31/12/09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Neal Bradsher
BRD | Director/Board Member | 58 | 30/06/09 |
Brian Culley
CEO | Chief Executive Officer | 53 | 16/09/18 |
Deborah Andrews
BRD | Director/Board Member | 66 | 10/04/14 |
1st Jan change | Capi. | |
---|---|---|
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
+10.74% | 25.92B | |
-13.50% | 26.03B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B | |
-12.61% | 10.64B |